A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Uterine cancer
- Focus Therapeutic Use
- 18 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 09 Apr 2019 Status changed from suspended to recruiting.